Literature DB >> 28179292

Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice.

Hossein Jadvar1, Ryan Park2, Li-Peng Yap2, Kai Chen2, Lindsey Hughes2, Peter Conti2.   

Abstract

AIM: We assessed the association between the presence and absence of androgen on the normal biodistribution of the positron emission tomography (PET) cellular proliferation imaging biomarker, [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU), in mice.
MATERIALS AND METHODS: Non-castrated (n=4) and castrated (n=4) athymic non-tumor-bearing male mice served as models for presence and absence, respectively, of androgen. MicroPET-CT scans were performed 1 h following tail vein administration of 200 uCi of 18F-FMAU. Imaging was performed at baseline and then at 7-day intervals longitudinally for 35 days only in castrated mice following subcutaneous introduction of a 12.5 mg, 21-day release, dihydrotestosterone pellet. Mean standardized uptake values (SUVmean) were obtained for liver, heart, and muscle. Several two-group comparisons of average of SUVmean were performed.
RESULTS: Pre-pellet baseline average SUVmean (±s.d.) values in castrated mice were significantly lower than baseline non-castrated values, increased on day 15 and reached peak values on day 28, at which time they were significantly higher than corresponding baseline levels in both non-castrated and pre-pellet castrated mice. The peak values decreased significantly following dihydrotestosterone withdrawal.
CONCLUSION: There is a significant modulatory effect of androgen on normal 18F-FMAU uptake levels in mice liver, heart and muscle tissues. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Androgen; FMAU; PET; prostate

Mesh:

Substances:

Year:  2017        PMID: 28179292      PMCID: PMC5404414          DOI: 10.21873/anticanres.11339

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo.

Authors:  J R Grierson; A F Shields
Journal:  Nucl Med Biol       Date:  2000-02       Impact factor: 2.408

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  Androgen control of mitochondrial and nuclear DNA synthesis in male sex accessory tissue of castrate rats.

Authors:  K A Doeg; L L Polomski; L H Doeg
Journal:  Endocrinology       Date:  1972-06       Impact factor: 4.736

Review 4.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

5.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.

Authors:  A F Shields; D Mankoff; M M Graham; M Zheng; S M Kozawa; J M Link; K A Krohn
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

7.  Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT.

Authors:  Hossein Jadvar; Kai Chen; Osamu Ukimura
Journal:  Clin Nucl Med       Date:  2015-08       Impact factor: 7.794

Review 8.  PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.

Authors:  Harshad R Kulkarni; Aviral Singh; Christiane Schuchardt; Karin Niepsch; Manal Sayeg; Yevgeniy Leshch; Hans-Juergen Wester; Richard P Baum
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

Review 9.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Authors:  Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

Review 10.  Pathology of prostate cancer and focal therapy ('male lumpectomy').

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Liang Cheng; Antonio Lopez-Beltran; Andrea B Galosi; Ziya Kirkali; Rodolfo Montironi
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.